	US 12,403,184 B2
	Compositions and methods for treating neurodegenerative disroders
Xin Qi, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Appl. No. 17/264,923
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
PCT Filed Jul. 31, 2019, PCT No. PCT/US2019/044465 § 371(c)(1), (2) Date Feb. 1, 2021, PCT Pub. No. WO2020/028549, PCT Pub. Date Feb. 6, 2020.
Claims priority of provisional application 62/712,776, filed on Jul. 31, 2018.
Prior Publication US 2021/0322524 A1, Oct. 21, 2021
Int. Cl. A61K 38/46 (2006.01); A61K 38/16 (2006.01); A61P 25/28 (2006.01)

CPC A61K 38/46 (2013.01) [A61K 38/162 (2013.01); A61P 25/28 (2018.01)]

16 Claims

1. A method of inhibiting aberrant ATPase family AAA-domain containing protein 3A (ATAD3A) activation and/or oligomerization in mitochondria of a cell, the method comprising:

administering to the cell a therapeutic peptide linked to a transport moiety, wherein

the therapeutic peptide consists of about 6 to about 12 amino acids and has at least about 80% sequence identity to about 6 to about 12 consecutive amino acids of an interaction site of dynamin-related protein 1 (Drp1) with a first coiled-coil domain of ATAD3A, and inhibits binding or complexing of ATAD3A with Drp-1 in the mitochondria of the cell; and

wherein the transport moiety facilitates uptake of the therapeutic peptide by a nerve cell.